Abstract

Patients with triple-negative breast cancer (TNBC) who relapse early after (neo)adjuvant chemotherapy have more aggressive disease. In the ASCENT trial, sacituzumab govitecan (SG), an antibody-drug conjugate composed of an anti-Trop–2 antibody coupled to SN-38 via a hydrolyzable linker, improved outcomes over single-agent chemotherapy of physician’s choice (TPC) in metastatic TNBC (mTNBC). Of 468 patients without known baseline brain metastases, 33/235 vs 32/233 patients (both 14%) in the SG vs TPC arms, respectively, received one line of therapy in the metastatic setting and experienced disease recurrence ≤12 months after (neo)adjuvant chemotherapy. SG prolonged progression-free survival (median 5.7 vs 1.5 months [HR, 0.41; 95% CI, 0.22–0.76]) and overall survival (median 10.9 vs 4.9 months [HR, 0.51; 95% CI, 0.28–0.91]) vs TPC, with a manageable safety profile in this subgroup consistent with the overall population. In this second-line setting, as with later-line therapy, SG improved survival over conventional chemotherapy for patients with mTNBC.

Details

Title
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
Author
Carey, Lisa A. 1   VIAFID ORCID Logo  ; Loirat, Delphine 2 ; Punie, Kevin 3   VIAFID ORCID Logo  ; Bardia, Aditya 4 ; Diéras, Véronique 5   VIAFID ORCID Logo  ; Dalenc, Florence 6 ; Diamond, Jennifer R. 7 ; Fontaine, Christel 8 ; Wang, Grace 9 ; Rugo, Hope S. 10 ; Hurvitz, Sara A. 11   VIAFID ORCID Logo  ; Kalinsky, Kevin 12 ; O’Shaughnessy, Joyce 13 ; Loibl, Sibylle 14 ; Gianni, Luca 15   VIAFID ORCID Logo  ; Piccart, Martine 16 ; Zhu, Yanni 17 ; Delaney, Rosemary 18 ; Phan, See 19 ; Cortés, Javier 20   VIAFID ORCID Logo 

 University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA (GRID:grid.10698.36) (ISNI:0000000122483208) 
 Medical Oncology Department and D3i, Institut Curie, Paris, France (GRID:grid.418596.7) (ISNI:0000 0004 0639 6384) 
 University Hospitals Leuven, Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, Leuven, Belgium (GRID:grid.410569.f) (ISNI:0000 0004 0626 3338) 
 Massachusetts General Hospital Cancer Center, Harvard Medical School, Department of Hematology/Oncology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Centre Eugène Marquis, Department of Medical Oncology, Rennes, France (GRID:grid.417988.b) (ISNI:0000 0000 9503 7068) 
 Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France (GRID:grid.417829.1) (ISNI:0000 0000 9680 0846) 
 University of Colorado Anschutz Medical Campus, Division of Medical Oncology, Department of Medicine, Aurora, USA (GRID:grid.430503.1) (ISNI:0000 0001 0703 675X) 
 Oncologisch Centrum, UZ Brussel, Medical Oncology Department, Brussels, Belgium (GRID:grid.411326.3) (ISNI:0000 0004 0626 3362) 
 Miami Cancer Institute, Miami, USA (GRID:grid.418212.c) (ISNI:0000 0004 0465 0852) 
10  University of California San Francisco Helen Diller Family Comprehensive Cancer Center, Department of Medicine, San Francisco, USA (GRID:grid.511215.3) (ISNI:0000 0004 0455 2953) 
11  University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718) 
12  Winship Cancer Institute, Emory University, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502) 
13  Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, USA (GRID:grid.411588.1) (ISNI:0000 0001 2167 9807) 
14  Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Department of Medicine and Research, Frankfurt, Germany (GRID:grid.411588.1) 
15  Gianni Bonadonna Foundation, Medical Oncology, Milan, Italy (GRID:grid.411588.1) 
16  Institut Jules Bordet and l’Université Libre de Bruxelles, Medical Oncology Department, Brussels, Belgium (GRID:grid.4989.c) (ISNI:0000 0001 2348 0746) 
17  Gilead Sciences, Inc, Department of Biostatistics, Foster City, USA (GRID:grid.418227.a) (ISNI:0000 0004 0402 1634) 
18  Gilead Sciences, Inc, Department of Clinical Research, Morris Plains, USA (GRID:grid.418227.a) (ISNI:0000 0004 0402 1634) 
19  Gilead Sciences Inc, Department of Clinical Development, Foster City, USA (GRID:grid.418227.a) (ISNI:0000 0004 0402 1634) 
20  Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Vall d´Hebron Institute of Oncology (VHIO), International Breast Cancer Center, Quirón Group, Barcelona, Barcelona, Spain (GRID:grid.411083.f) (ISNI:0000 0001 0675 8654) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
23744677
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2674579036
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.